Price to Book Value Chart

View Price to Book Value for ORMP.
Upgrade now.
Sep '18
Jan '19
May '19
 
285.00
270.00
255.00
240.00
View Price to Book Value Chart
Start Trial

Historical Price to Book Value Data

View and export this data back to 2007. Start Trial.
Date Value
August 25, 2026 0.678
August 24, 2026 0.6272
August 21, 2026 0.6259
August 20, 2026 0.6233
August 19, 2026 0.6233
August 18, 2026 0.622
August 17, 2026 0.5947
August 14, 2026 0.583
August 13, 2026 0.57
August 12, 2026 0.5557
August 11, 2026 0.5531
August 10, 2026 0.5466
August 07, 2026 0.5596
August 06, 2026 0.5596
August 05, 2026 0.5622
August 04, 2026 0.5804
August 03, 2026 0.5713
July 31, 2026 0.5296
July 30, 2026 0.5362
July 29, 2026 0.5166
July 28, 2026 0.5427
July 27, 2026 0.5414
July 24, 2026 0.5244
July 23, 2026 0.5414
July 22, 2026 0.5231
Date Value
July 21, 2026 0.5231
July 20, 2026 0.5336
July 17, 2026 0.5244
July 16, 2026 0.527
July 15, 2026 0.5283
July 14, 2026 0.5205
July 13, 2026 0.5147
July 10, 2026 0.5257
July 09, 2026 0.544
July 08, 2026 0.5583
July 07, 2026 0.5596
July 06, 2026 0.5947
July 02, 2026 0.5986
July 01, 2026 0.5999
June 30, 2026 0.6259
June 29, 2026 0.797
June 26, 2026 0.8021
June 25, 2026 0.8588
June 24, 2026 0.7386
June 23, 2026 0.7162
June 22, 2026 0.6888
June 18, 2026 0.6664
June 17, 2026 0.651
June 16, 2026 0.6475
June 15, 2026 0.6596

Price to Book Ratio Definition

Price to book value is a valuation ratio that is measured by stock price / book value per share. The book value is essentially the tangible accounting value of a firm compared to the market value that is shown.

Read full definition.

Price to Book Value Range, Past 5 Years

View Price to Book Value Range, Past 5 Years
Start Trial
--
Minimum
--
Maximum
--
Average
--
Median

Price to Book Value Benchmarks

View Price to Book Value Benchmarks
Start Trial
Eli Lilly & Co. 33.28
Pfizer Inc. 1.902
Yarrow Bioscience, Inc. 1.241
Liquidia Corp. 32.85
NRX Pharmaceuticals, Inc. --

Price to Book Value Related Metrics

PE Ratio 1.272
Price 5.23
Earnings Yield 78.59%
Market Cap 216.07M
Normalized PE Ratio 4.989